16:37:12 EST Thu 14 Nov 2019
Enter Symbol
or Name
USA
CA



Callitas Health Inc
Symbol LILY
Shares Issued 32,462,095
Close 2018-03-12 C$ 0.32
Recent Sedar Documents

Callitas Health hires TraDigitalIR for IR services

2018-03-13 12:34 ET - News Release

Mr. James Thompson reports

CALLITAS HEALTH ANNOUNCES SELECTION OF TRADIGITALIR AS INVESTOR AND PUBLIC RELATIONS ADVISOR

Callitas Health Inc. has hired TraDigitalIR as its investor and public relations agency of record. Effective March 1, 2018, TraDigitalIR began providing a full suite of marketing, communications and investor relations services.

James Thompson, chief executive officer of Callitas Health, stated: "As we enter a new phase of product research and development, business expansion and strategic partnering, the management team at Callitas Health understands the importance of better communicating our story to the right audience. The team at TraDigitalIR presented a strong knowledge of our business and created a strategic plan including traditional and digital communications. We look forward to working closely with TraDigitalIR to convey our business story, growth strategy, competitive advantages, and value proposition to the investment community."

Sean Leous, managing director of public relations of TraDigitalIR, commented: "We are pleased to have been appointed as investor and public relations adviser to Callitas Health. With an expanding product offering, strong pharmaceutical and OTC products pipeline, and strengthened management team, we believe the business is well positioned for growth. We look forward to partnering with Callitas Health to enhance its communication with investors and improve market awareness of the company."

About Callitas Health Inc.

Formed in early 2015, Callitas Health is a clinical-stage company developing innovative pharmaceutical and OTC technologies for weight management, and female sexual health and wellness, targeted cannabinoid delivery and other proprietary drugs. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J's LLC, the company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive.

© 2019 Canjex Publishing Ltd. All rights reserved.